Litcius/Paper detail

Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial

Merit Cudkowicz, Angela Genge, Nicholas J. Maragakis, Susanne Petri, Leonard van den Berg, Valtteri V. Aho, Toni Sarapohja, Mikko Kuoppamäki, Chris Garratt, Ammar Al‐Chalabi, Matthew C. Kiernan, Susan Mathers, Robert D. Henderson, Merrilee Needham, David Schultz, Wolfgang N. Löscher, Nenad Mitrović, Jakob Rath, Philip Van Damme, Jan De Bleecker, Stéphanie Delstanche, Wendy Johnston, Lorne Zinman, Colleen O’Connell, Geneviève Matte, Annie Dionne, Lawrence Korngut, John Turnbull, Hannu Laaksovirta, Manu Jokela, Tero Tapiola, Marie‐Hélène Soriani, Philippe Couratier, William Camu, Philippe Corcia, Albert C. Ludolph, Julian Großkreutz, Thomas Meyer, Matthias Boentert, Berthold Schrank, Johannes Prudlo, Robert Untucht, Orla Hardiman, Gabriele Siciliano, Adriano Chiò, Letizia Mazzini, Maurizio Inghilleri, Claudia Caponnetto, Gabriele Mora, Jesús S. Mora Pardina, Eva Farrero Muñoz, Juan F. Vázquez‐Costa, Eduardo Agüera, Luís Varona, Peter Andersen, Caroline Ingre, Rune Johansson, Aleksandar Radunović, Carolyn Young, Suma Babu, Aziz Shaibani, Nathan P. Staff, Tuan Vu, Michael H. Rivner, Stephen N. Scelsa, Kumaraswamy Sivakumar, Waqar Waheed, Daragh Heitzman, Sandeep Rana, Gary L. Pattee, Senda Ajroud‐Driss, Elham Bayat, Edward J. Kasarskis, Dale J. Lange, Michael A. Elliott, Brent T. Harris, Kevin J. Felice, Michael Pulley, Justin Kwan, M. Brown, John Ravits, Matthew Burford, Chafic Karam, Timothy M. Miller, Jinsy Andrews, Todd Levine, Eduardo Locatelli, James Wymer, Richard Bedlack, Dominic Fee, Namita Goyal, Björn Oskarsson, Leo McCluskey, James B. Caress, Michael D. Weiss, Adam Quick, Mark B. Bromberg, David Lacomis, Stephen A. Goutman, Kourosh Rezania

2021The Lancet Neurology19 citationsDOIOpen Access PDF

Topics & Concepts

MedicineAmyotrophic lateral sclerosisClinical endpointPlaceboLevosimendanAdverse effectPopulationInternal medicinePhysical therapyRiluzoleClinical trialHeart failurePathologyDiseaseAlternative medicineEnvironmental healthAmyotrophic Lateral Sclerosis ResearchNeurogenetic and Muscular Disorders ResearchCervical and Thoracic Myelopathy
Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial | Litcius